European Medicines Agency Recommends Approval of <a href="https://laohu8.com/S/ALVO">Alvotech</a>'s AVT06, Proposed Biosimilar to Eylea®
Alvotech SA, in collaboration with Advanz Pharma, announced that the European Medicines Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has adopted a positive opinion recommending market approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). This recommendation is a significant step towards marketing the biosimilar in the European Economic Area, which includes the 27 EU member states, Norway, Iceland, and Lichtenstein. The approval is intended for treating various eye disorders, including neovascular age-related macular degeneration and diabetic macular oedema. Alvotech is responsible for the development and commercial supply, while Advanz Pharma holds exclusive commercialization rights in most European countries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114182-en) on June 23, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。